<p>Caris Life Sciences, Inc. (NASDAQ:CAI - 获取免费报告) 的股价在周一创下 52 周新低。该股最低交易价为 22.80 美元，最后交易价为 23.56 美元，成交量为 169898 股。该股此前收盘价为 23.16 美元。</p>
<p>获取 <strong>Caris Life Sciences</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>几家券商最近对 CAI 进行了评论。华尔街 Zen 在 1 月 17 日的报告中将 Caris Life Sciences 的评级从 “持有” 上调至 “买入”。Evercore ISI 在 1 月 5 日的研究报告中设定了 Caris Life Sciences 的目标价为 38.00 美元。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Caris Life Sciences 的 “卖出（d）” 评级。最后，Canaccord Genuity Group 在 12 月 22 日的报告中将 Caris Life Sciences 的目标价从 28.00 美元上调至 30.00 美元，并给予该股 “持有” 评级。一位研究分析师对该股给予了 “持有” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “减持”，共识目标价为 34.00 美元。</p>
<p><strong>查看我们关于 CAI 的最新报告</strong></p>
<h2>Caris Life Sciences 股票表现</h2>
<p>该公司的债务与股本比率为 0.79，流动比率为 9.93，速动比率为 9.36。该股市值为 65.9 亿美元，市盈率为-50.80。</p>
<h2>Caris Life Sciences 的内部交易</h2>
<p>在其他新闻中，内部人士 Luke Thomas Power 在 12 月 11 日的交易中出售了 62,250 股该公司的股票。股票以平均价格 26.58 美元出售，总价值为 1,654,605.00 美元。交易后，内部人士持有 99,571 股公司的股票，价值约为 2,646,597.18 美元。此次交易代表其持股减少了 38.47%。该出售在向证券交易委员会提交的文件中披露，文件可通过此超链接获取。内部人士持有公司 7.80% 的股份。</p>
<h2>Caris Life Sciences 的机构交易</h2>
<p>一些机构投资者和对冲基金最近调整了对 CAI 的持股。Diversified Trust Co.在第四季度以 540,000 美元的估值新建了对 Caris Life Sciences 的持仓。Olistico Wealth LLC 在第四季度以约 31,000 美元的价值购买了 Caris Life Sciences 的新股份。Zevenbergen Capital Investments LLC 在第四季度以约 14,655,000 美元的价值新建了对 Caris Life Sciences 的股份。Hamilton Lane Advisors LLC 在第四季度以约 1,584,000 美元的估值新建了对 Caris Life Sciences 的持仓。最后，Sumitomo Mitsui Trust Group Inc.在第四季度将其在 Caris Life Sciences 的股份增加了 26.5%。Sumitomo Mitsui Trust Group Inc.现在拥有 75,330 股公司的股票，价值 2,032,000 美元，此前在上个季度又购买了 15,778 股。</p>
<h2>Caris Life Sciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Caris Life Sciences NASDAQ: CAI 是一家分子科学公司，专注于推进肿瘤学中的精准医学。该公司开发并提供全面的分子分析服务，旨在识别 DNA、RNA 和蛋白质模式中的可操作生物标志物。其临床服务旨在通过根据肿瘤生物学将患者与靶向疗法、免疫疗法和相关临床试验匹配，来支持肿瘤科医生的治疗决策。</p>
<p>Caris 提供基于实验室的诊断测试及相关解释报告，结合高通量测序和其他分子技术与生物信息学分析。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Caris Life Sciences</li>
<li>股票代码揭晓：对 “下一个埃隆·马斯克” 公司的 IPO 前访问</li>
<li>华尔街警报：买入 AES</li>
<li>黄金警报</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>一项价值数万亿的美国 “出生权” 声明 - 静悄悄地激活</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Caris Life Sciences 吗？</h2>
<p>在考虑 Caris Life Sciences 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Caris Life Sciences 并不在名单上。</p>
<p>虽然 Caris Life Sciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Caris Life Sciences (NASDAQ:CAI) 的股票在 $22.80 达到新的 52 周低点，收盘价为 $23.56，交易量为 169,898 股。分析师们的意见不一，Wall Street Zen 将该股票评级上调至 “买入”，而 Weiss Ratings 维持 “卖出” 评级。该股票的共识评级为 “减持”，目标价为 $34.00。内部人士 Luke Thomas Power 出售了 62,250 股，减少了 38.47% 的持股比例。该公司专注于肿瘤学领域的精准医疗，提供分子分析服务</p>

<p>Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report)'s share price hit a new 52-week low on Monday . The stock traded as low as $22.80 and last traded at $23.56, with a volume of 169898 shares. The stock had previously closed at $23.16.</p>
<div class="lb-trans"><p>Caris Life Sciences, Inc. (NASDAQ:CAI - 获取免费报告) 的股价在周一创下 52 周新低。该股最低交易价为 22.80 美元，最后交易价为 23.56 美元，成交量为 169898 股。该股此前收盘价为 23.16 美元。</p>
</div><p>Get <strong>Caris Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Caris Life Sciences</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several brokerages have recently commented on CAI. Wall Street Zen raised Caris Life Sciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, January 17th. Evercore ISI set a $38.00 price objective on Caris Life Sciences in a research note on Monday, January 5th. Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Finally, Canaccord Genuity Group increased their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a &#34;hold&#34; rating in a report on Monday, December 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $34.00.</p>
<div class="lb-trans"><p>几家券商最近对 CAI 进行了评论。华尔街 Zen 在 1 月 17 日的报告中将 Caris Life Sciences 的评级从 “持有” 上调至 “买入”。Evercore ISI 在 1 月 5 日的研究报告中设定了 Caris Life Sciences 的目标价为 38.00 美元。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Caris Life Sciences 的 “卖出（d）” 评级。最后，Canaccord Genuity Group 在 12 月 22 日的报告中将 Caris Life Sciences 的目标价从 28.00 美元上调至 30.00 美元，并给予该股 “持有” 评级。一位研究分析师对该股给予了 “持有” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “减持”，共识目标价为 34.00 美元。</p>
</div><p><strong>View Our Latest Report on CAI</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CAI 的最新报告</strong></p>
</div><h2>Caris Life Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Caris Life Sciences 股票表现</h2>
</div><p>The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36. The stock has a market capitalization of $6.59 billion and a price-to-earnings ratio of -50.80.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.79，流动比率为 9.93，速动比率为 9.36。该股市值为 65.9 亿美元，市盈率为-50.80。</p>
</div><h2>Insider Transactions at Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的内部交易</h2>
</div><p>In other news, insider Luke Thomas Power sold 62,250 shares of the firm's stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total value of $1,654,605.00. Following the transaction, the insider owned 99,571 shares of the company's stock, valued at approximately $2,646,597.18. This trade represents a 38.47% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own 7.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Luke Thomas Power 在 12 月 11 日的交易中出售了 62,250 股该公司的股票。股票以平均价格 26.58 美元出售，总价值为 1,654,605.00 美元。交易后，内部人士持有 99,571 股公司的股票，价值约为 2,646,597.18 美元。此次交易代表其持股减少了 38.47%。该出售在向证券交易委员会提交的文件中披露，文件可通过此超链接获取。内部人士持有公司 7.80% 的股份。</p>
</div><h2>Institutional Trading of Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of CAI. Diversified Trust Co. acquired a new position in shares of Caris Life Sciences in the 4th quarter valued at $540,000. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the fourth quarter worth about $31,000. Zevenbergen Capital Investments LLC acquired a new stake in shares of Caris Life Sciences during the fourth quarter worth about $14,655,000. Hamilton Lane Advisors LLC acquired a new position in shares of Caris Life Sciences in the 4th quarter valued at approximately $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Caris Life Sciences by 26.5% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company's stock worth $2,032,000 after purchasing an additional 15,778 shares in the last quarter.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了对 CAI 的持股。Diversified Trust Co.在第四季度以 540,000 美元的估值新建了对 Caris Life Sciences 的持仓。Olistico Wealth LLC 在第四季度以约 31,000 美元的价值购买了 Caris Life Sciences 的新股份。Zevenbergen Capital Investments LLC 在第四季度以约 14,655,000 美元的价值新建了对 Caris Life Sciences 的股份。Hamilton Lane Advisors LLC 在第四季度以约 1,584,000 美元的估值新建了对 Caris Life Sciences 的持仓。最后，Sumitomo Mitsui Trust Group Inc.在第四季度将其在 Caris Life Sciences 的股份增加了 26.5%。Sumitomo Mitsui Trust Group Inc.现在拥有 75,330 股公司的股票，价值 2,032,000 美元，此前在上个季度又购买了 15,778 股。</p>
</div><h2>Caris Life Sciences Company Profile</h2>
<div class="lb-trans"><h2>Caris Life Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.</p>
<div class="lb-trans"><p>Caris Life Sciences NASDAQ: CAI 是一家分子科学公司，专注于推进肿瘤学中的精准医学。该公司开发并提供全面的分子分析服务，旨在识别 DNA、RNA 和蛋白质模式中的可操作生物标志物。其临床服务旨在通过根据肿瘤生物学将患者与靶向疗法、免疫疗法和相关临床试验匹配，来支持肿瘤科医生的治疗决策。</p>
</div><p>Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.</p>
<div class="lb-trans"><p>Caris 提供基于实验室的诊断测试及相关解释报告，结合高通量测序和其他分子技术与生物信息学分析。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Caris Life Sciences</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>Wall Street Alert: Buy AES</li>
<li>GOLD ALERT</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Caris Life Sciences</li>
<li>股票代码揭晓：对 “下一个埃隆·马斯克” 公司的 IPO 前访问</li>
<li>华尔街警报：买入 AES</li>
<li>黄金警报</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>一项价值数万亿的美国 “出生权” 声明 - 静悄悄地激活</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Caris Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Caris Life Sciences 吗？</h2>
</div><p>Before you consider Caris Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Caris Life Sciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caris Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Caris Life Sciences 并不在名单上。</p>
</div><p>While Caris Life Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Caris Life Sciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Caris Life Sciences (NASDAQ:CAI) 创下新的一年低点 - 现在是卖出的时候吗？